Michael Bonney Net Worth

The estimated Net Worth of Michael W Bonney is at least $1.35 Million dollars as of 9 September 2019. Mr. Bonney owns over 2,000 units of Alnylam Pharmaceuticals stock worth over $646,859 and over the last 8 years he sold ALNY stock worth over $0. In addition, he makes $704,923 as Independent Chairman of the Board at Alnylam Pharmaceuticals.

Mr. Bonney ALNY stock SEC Form 4 insider trading

Michael has made over 19 trades of the Alnylam Pharmaceuticals stock since 2012, according to the Form 4 filled with the SEC. Most recently he bought 2,000 units of ALNY stock worth $173,480 on 9 September 2019.

The largest trade he’s ever made was buying 71,520 units of Alnylam Pharmaceuticals stock on 28 February 2019 worth over $999,850. On average, Michael trades about 2,426 units every 62 days since 2012. As of 9 September 2019 he still owns at least 7,051 units of Alnylam Pharmaceuticals stock.

You can see the complete history of Mr. Bonney stock trades at the bottom of the page.

Michael Bonney biography

Michael W. Bonney is Independent Chairman of the Board of the Alnylam Pharmaceuticals, Inc. Mr. Bonney has served as the Executive Chair of Kaleido Biosciences, a biotechnology company, since June 2017. From June 2017 until August 2018, he also served as Kaleido’s Chief Executive Officer. Mr. Bonney was a Partner at Third Rock Ventures, a healthcare venture firm, from January to July 2016. Mr. Bonney previously served as the Chief Executive Officer and a member of the board of directors of Cubist Pharmaceuticals, Inc., a biopharmaceutical company (now a wholly-owned subsidiary of Merck & Co., Inc.), from June 2003 until his retirement in December 2014. From January 2002 to June 2003, he served as Cubist’s President and Chief Operating Officer. In addition, Mr. Bonney is the Chair of the board of directors of Magenta Therapeutics, Inc. and serves as a director of Celgene Corporation, Syros Pharmaceuticals, Inc. and Sarepta Therapeutics, Inc. Mr. Bonney formerly served as a director of Global Blood Therapeutics, Inc., NPS Pharmaceuticals, Inc. and Cubist.

What is the salary of Michael Bonney?

As the Independent Chairman of the Board of Alnylam Pharmaceuticals, the total compensation of Michael Bonney at Alnylam Pharmaceuticals is $704,923. There are 6 executives at Alnylam Pharmaceuticals getting paid more, with Laurie Keating having the highest compensation of $5,305,000.

How old is Michael Bonney?

Michael Bonney is 61, he’s been the Independent Chairman of the Board of Alnylam Pharmaceuticals since 2016. There are 8 older and 7 younger executives at Alnylam Pharmaceuticals. The oldest executive at Alnylam Pharmaceuticals, Inc. is Paul Schimmel, 78, who is the Independent Director.

What’s Michael Bonney’s mailing address?

Michael’s mailing address filed with the SEC is 215 FIRST STREET, , CAMBRIDGE, MA, 012142.

Insider trading at Alnylam Pharmaceuticals

Over the last 15 years, insiders at Alnylam Pharmaceuticals have traded over $82,632,558 worth of Alnylam Pharmaceuticals stock and bought 4,419,116 units worth $1,983,132,563 . The most active insider traders include Sanofi, Christoph H Westphal, and Kevin P Starr. On average, Alnylam Pharmaceuticals executives and independent directors trade stock every 25 days with the average trade being worth of $5,003,746. The most recent stock trade was executed by Barry E Greene on 22 October 2019, trading 58,913 units of ALNY stock currently worth $967,941.

What does Alnylam Pharmaceuticals do?

Alnylam Pharmaceuticals, Inc. operates as biopharmaceutical company, which engages in the discovery, development and commercialization of RNAi therapeutics. It is the translation of RNAi as a new class of innovative medicines with a core focus on RNAi therapeutics for the treatment of genetically defined diseases. The company was founded by John Kennedy Clarke, Paul R. Schimmel and Phillip A. Sharp on June 14, 2002 and is headquartered in Cambridge, MA.

What does Alnylam Pharmaceuticals’s logo look like?

Complete history of Mr. Bonney stock trades at Alnylam Pharmaceuticals, Celgene, Global Blood Therapeutics, Sarepta Therapeutics, Syros Pharmaceuticals, Tekla Healthcare Investors, Tekla Life Sciences Investors, Tekla Healthcare Opportunities Fund, Tekla World Healthcare Fund, Magenta Therapeutics, and Kaleido Biosciences

Alnylam Pharmaceuticals executives and stock owners

Alnylam Pharmaceuticals executives and other stock owners filed with the SEC include:

  • Laurie Keating, Executive Vice President, Chief Legal Officer, Secretary
  • John Maraganore, Chief Executive Officer, Director
  • Barry Greene, President
  • Yvonne Greenstreet, Chief Operating Officer
  • Akshay Vaishnaw, President – Research and Development
  • Manmeet Soni, Chief Financial Officer, Senior Vice President, Principal Financial Officer and Principal Accounting Officer
  • Colleen Reitan, Independent Director
  • Michael Bonney, Independent Chairman of the Board
  • Phillip Sharp, Independent Director
  • Marsha Fanucci, Independent Director
  • Amy Schulman, Independent Director
  • Paul Schimmel, Independent Director
  • Steven Paul, Independent Director
  • David Pyott, Independent Director
  • Dennis Ausiello, Independent Director
  • Margaret Hamburg, Independent Director
  • Kevin Fitzgerald, Senior Vice President, Chief Scientific Officer
  • Kelley Boucher, Chief Human Resource Officer, Senior Vice President
  • David Alexandre C Gros, SVP, Chief Business Officer
  • Kevin P Starr, Director
  • Sanofi, 10% owner
  • Michael Mason, VP, Finance and Treasurer
  • John K Clarke, Director
  • Venture Management Co Iii L…, 10% owner
  • Victor J Dzau, Director
  • Agnovartis Pharma Ag Novartis,
  • Venture Management Co Iii L…,
  • Peter Barrett, Director
  • Christoph H Westphal, Director
  • Venture Fund V Lpatlas Vent…,
  • Venture Management Co Iii L…,
  • Ii Lp Chp, 10% owner
  • Kenneth S Koblan, Chief Scientific Officer
  • Laurence Reid, SVP, Chief Business Officer
  • Vicki L Sato, Director
  • Management Ltd Abingworth, 10% owner
  • John A Jr Schmidt, SVP, Chief Scientific Officer
  • Patricia L Allen, VP Finance and Treasurer
  • Venture Fund V Lpatlas Vent…,
  • John E Berriman, Director
  • Vincent J Miles, Senior VP Business Development
  • James L Vincent, Director
  • Venture Fund V Lpatlas Vent…,
  • Edward M Scolnick, Director